7,639.25

+25.25

+0.33%

52,056.00

+138.00

+0.27%

28,729.00

+195.00

+0.68%

Russell 2000 Futures

2,832.90

+11.60

+0.41%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,919.30

+20.40

+0.52%

78,471.00

+884.90

+1.14%

Crude Oil Dec 26

101.76

-2.36

-2.27%

US Private Equity

10,850.63

-82.20

-0.75%

SES - Delayed Quote SGD

Clearbridge Health Limited (1H3.SI)

0.0010 0.0000 (0.00%)

As of October 29 at 4:58:15 PM GMT+8. Market Open.

Loading Chart for 1H3.SI

Chart Range Bar

Interval:

In partnership with ChartIQ

Stock futures open a monster week after a $5 trillion AI wipeout

Stock futures open a monster week after a $5 trillion AI wipeout

Need a break from AI stocks? Here's how Warren Buffett still looms over red-hot Brooks Running.

Need a break from AI stocks? Here's how Warren Buffett still looms over red-hot Brooks Running.

A big sell-off collides with more Big Tech earnings and a midterm election: What to watch this week

Dow Jones Futures Rise After Market Sell-Off; How Midterm Elections May Swing Stocks

Dow Jones Futures Rise After Market Sell-Off; How Midterm Elections May Swing Stocks

U.S. stock futures edge high after bruising Oct; earnings, elections in focus

U.S. stock futures edge high after bruising Oct; earnings, elections in focus

Titan Minerals expands Dynasty gold system in September quarter as Linderos copper JV advances

Titan Minerals expands Dynasty gold system in September quarter as Linderos copper JV advances

Wall Street Has Never Faced This Many Market Forces at Once, NYSE Veteran Says

Wall Street Has Never Faced This Many Market Forces at Once, NYSE Veteran Says

Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch

Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch

Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch

Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

Mobilize your Website

View Site in Mobile | Classic

Share by: